Ademi Zanfina, Rodda Sheridan E, Vivoda Karl, Hennessy Susan, Fenton Olive, Ware James S
Health Economics and Policy Evaluation Research, Faculty of Pharmacy and Pharmaceutical Sciences, Centre for Medicine Use and Safety, Monash University, Parkville, VIC, Australia.
University of California, San Francisco, USA.
Pharmacoeconomics. 2025 Sep 8. doi: 10.1007/s40273-025-01537-5.
Cardiovascular disease (CVD) is a major contributor to the health and economic burden of disease globally. In this paper we discuss the literature on the health economics of the prevention and early intervention in CVD. We reveal the large economic impact of CVD and provide the economic argument supporting the calls for early detection and diagnosis of CVD outlined in the Global Heart Hub's patient-led Manifesto for Change. Many challenges in conducting cost-effectiveness analyses of interventions for CVD prevention are identified, as well as the emerging statistical and economic methods to help overcome these issues. Lastly, we acknowledge the profound disparities in cardiovascular health faced by minority or underserved populations, and the important role that prevention and early intervention can play in improving health equity.
心血管疾病（CVD）是全球疾病健康和经济负担的主要促成因素。在本文中，我们讨论了有关心血管疾病预防和早期干预的健康经济学文献。我们揭示了心血管疾病的巨大经济影响，并提供了经济论据，以支持《全球心脏中心患者主导的变革宣言》中提出的对心血管疾病进行早期检测和诊断的呼吁。我们还指出了在进行心血管疾病预防干预措施的成本效益分析时面临的诸多挑战，以及有助于克服这些问题的新兴统计和经济方法。最后，我们认识到少数群体或服务不足人群在心血管健康方面面临的巨大差距，以及预防和早期干预在改善健康公平方面可以发挥的重要作用。
